Regulatory Science Symposium: Patient-Centered Drug Development and Real World Evidence/Data Session 2: History, Terms and Definitions (2019)

Course Syllabus/Topics:

  1. Topics covered
    1. Patient Focused Drug Development (PFDD)
    2. Real World Evidence/Data
    3. Goals for today
  2. Terminology
    1. Patient Focused or Centered Drug Development
  3. Prescription Drug User Fee Act
  4. History of Patient Focused Drug Development
  5. 21st Century Cures Act
  6. FDA (Draft) Guidance
  7. What else is in the CURES Act?
  8. Definitions
    1. Real World Data
    2. Real World Evidence
    3. Randomized Controlled Trials (RCT)
  9. Real World Data/Evidence
  10. Why Real World Data/Evidence?
  11. Current use of Real World Evidence/Data
  12. (MORE) Definitions
    1. Large Simple Trials (LST)
    2. Pragmatic Clinical Trials (PCT)
  13. RCT vs PCT – Internal and External Validity
  14. Future Use of RWD/E – FDA Framework
  15. Use of RWD/E in Decision Making
  16. FDA Investing in RWD/E
  17. Real World Data Possibilities
  18. Key Elements of Real World Data
    • Provenance
    • Lineage
    • Integrity
  19. Topics for Today


Accompanying text created by Khyati Ashtekar | Graduate Student, Regulatory Science, USC School of Pharmacy |  


NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.